Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apidra and Lantus in Pediatric Type 1 Diabetes
NCT01202474Phase 4Completed
- Sponsor
- Sanofi
- Start
- May 2011
- Primary completion
- Oct 2012
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of insulin glulisine in type 1 diabetes mellitus (T1D), sponsored by Sanofi. Primary endpoint: Percentage of patients achieving HbA1c level < 8% (6-12 yo) and < 7.5% (13-17 yo) at 12 months. Started May 2011; status: completed.
02
Drugs
insulin glulisine
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT01202474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01202474.